124 results on '"Rugeri, L."'
Search Results
2. Personalized thromboprophylaxis using a risk score for the management of pregnancies with high risk of thrombosis: a prospective clinical study
3. Comparison of an automated chemiluminescent assay to a manual ELISA assay for determination of von Willebrand Factor collagen binding activity on VWD plasma patients previously diagnosed through molecular analysis of VWF
4. Combined life-threatening thromboses and hemorrhages in a patient with afibrinogenemia and antithrombin deficiency
5. Diagnostic et prise en charge de la coagulopathie post-traumatique
6. Genotyping Might Help Therapeutic Decision Making in Patients with Von Willebrand Disease Type 2 B (VWD2B): OR07
7. Prospective evaluation of automatized PF4/heparin immunoassays HemosIL HIT-ab (PF4-H) for the diagnosis of heparin-induced thrombocytopenia
8. Diagnosis of early coagulation abnormalities in trauma patients by rotation thrombelastography
9. Comparison of hyperfibrinolysis in trauma and non-trauma patients
10. Biologic response to desmopressin is there predictable in patients from the same family?: PB 1.43–5
11. Von Willebrand factor activity determination using new assay principle ristocetin-free for reliable von Willebrand disease diagnosis: PA 1.09–2
12. Thrombin generation in patients with factor XI deficiency and clinical bleeding risk
13. Contribution of genetical analysis for diagnosis of von Willebrandʼs disease type 2B
14. A new electrophoretic variant of fibrinogen associated with venous thromboembolism, fibrinogen Bordeaux Aα Arg439→Cys
15. Evaluation of rotation thrombelastography for the diagnosis of hyperfibrinolysis in trauma patients
16. A new ELISA assay for diagnosis of acquired von Willebrand Syndrome
17. MATERNAL AND NEONATAL AUTOIMMUNE THROMBOCYTOPENIA
18. T-15-02: Efficacy, safety and consumption of plasma-derived von Willebrand factor (VWF)/Factor VIII (FVIII) concentrate with 2.4:1 VWF:FVIII ratio for the treatment of von Willebrand Disease: a systematic review.
19. Comparison of an automated chemiluminescent assay to a manual ELISA assay for determination of von Willebrand Factor collagen binding activity on VWD plasma patients previously diagnosed through molecular analysis of <italic>VWF</italic>.
20. A single-centre study of haemostatic outcomes of joint replacement in von Willebrand disease and control patients and an analysis of the literature.
21. Déficit combiné en facteurs V et VIII de la coagulation : ou quand la génétique nous explique les déficits combinés de facteurs de la coagulation
22. Thromboélastométrie rotative : réhabilitation de l'ancienne thromboélastographie
23. Intérêt des nouveaux marqueurs de la dégradation de la fibrine pour le calcul du score ISTH
24. Étude du profil thromboélastographique en transplantation rein-pancréas
25. OC-14 Pregnancy related thrombosis risk in patients with protein C deficiency
26. Utility of a point-of-care device for rapid determination of prothrombin time in trauma patients: a preliminary study.
27. Early coagulopathy in trauma patients: An on-scene and hospital admission study.
28. Place du fibrinogène dans le choc hémorragique chez un polytraumatisé : à propos d’un cas
29. Management of pregnant women with increased risk of venous thrombosis
30. Multiple arterial thromboses in a patient with primary antiphospholipid syndrome receiving a bromocriptine therapy.
31. Basic fibroblast growth factor increases tissue factor expression in circulating monocytes and in vascular wall.
32. P3 A score based prevention strategy of venous thromboembolism in pregnant women
33. After the SIPPET study: Position paper of the CoMETH, the French society of haemophilia.
34. MATERNAL AND NEONATAL AUTOIMMUNE THROMBOCYTOPENIA.
35. Impact d'une démarche qualité en sécurité transfusionnelle sur la prescription, l'optimisation des circuits, la traçabilité: Expérience du CHRU de Lille
36. Le déficit acquis en facteur V : une pathologie hémorragique rare à manifestations cliniques variables
37. Évaluation prospective sur 10 ans du score de Lyon dans la prévention de la maladie thromboembolique chez la femme enceinte. Résultats sur 445 patientes à risque.
38. A Systematic Review of Efficacy and Safety of Plasma-Derived von Willebrand Factor/Factor VIII Concentrate (Voncento) in von Willebrand Disease.
39. Surgery in rare bleeding disorders: the prospective MARACHI study.
40. Management of rare inherited bleeding disorders: Proposals of the French Reference Centre on Haemophilia and Rare Coagulation Disorders.
41. Multicolor flow cytometry in clinical samples for platelet signaling assessment.
42. Effectiveness of individualized management using WILFACTIN® in patients with von Willebrand disease during surgical procedures: A single-center study.
43. Continuous Infusion of Factor VIII and von Willebrand Factor in Surgery: Trials with pdFVIII LFB or pdVWF LFB in Patients with Bleeding Disorders.
44. Effectiveness of long-term prophylaxis using pdFVIII/VWF concentrate in patients with inherited von Willebrand disease.
45. Report of surgeries, their outcome and the thrombin generation assay in patients with Factor XI deficiency: A retrospective single-centre study.
46. Acquired factor V inhibitor: a nation-wide study of 38 patients.
47. Effectiveness and safety of hFVIII/VWF concentrate (Voncento ® ) in patients with inherited von Willebrand disease requiring surgical procedures: the OPALE multicentre observational study.
48. Management of previously untreated patients with severe haemophilia A preferentially treated with recombinant factor VIII products: Two French centres' real-life experience.
49. Gynecological and obstetric outcome in the French cohort of women with factor XIII deficiency.
50. Comparative Analysis of a French Prospective Series of 144 Patients with Heparin-Induced Thrombocytopenia (FRIGTIH) and the Literature.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.